Genmab A/S (OTCMKTS:GNMSF) Releases Earnings Results, Beats Estimates By $1.86 EPS

Genmab A/S (OTCMKTS:GNMSF) released its quarterly earnings results on Thursday. The company reported $5.42 EPS for the quarter, beating analysts’ consensus estimates of $3.56 by $1.86, Zacks reports. Genmab A/S had a return on equity of 15.34% and a net margin of 21.05%.

Genmab A/S Stock Performance

Shares of OTCMKTS:GNMSF traded up $5.00 during midday trading on Thursday, reaching $295.00. The company had a trading volume of 248 shares, compared to its average volume of 2,014. The company’s 50 day moving average price is $267.35 and its 200 day moving average price is $279.53. The company has a current ratio of 2.18, a quick ratio of 2.17 and a debt-to-equity ratio of 0.87. The stock has a market cap of $18.16 billion, a P/E ratio of 22.25 and a beta of 0.77. Genmab A/S has a 52-week low of $232.30 and a 52-week high of $352.00.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.